Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378106 | 1.00 | MAPT (0.48) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL27870517 | 0.81 | TDP1 (0.41) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL6802898 | 0.79 | HCAR2 (0.47) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL11105775 | 0.78 | MAPT (0.40) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL11105770 | 0.78 | MAPT (0.40) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL23235417 | 0.76 | CYP2C9 (0.46) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL1061842 | 0.76 | CYP2C9 (0.46) | MAPTMEN1KMT2AGAATDP1 | |
| SCHEMBL10419352 | 0.76 | TDP1 (0.42) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL14279186 | 0.76 | POLB (0.54) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL10419353 | 0.76 | TDP1 (0.42) | MAPTMEN1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746428-B | MCL1 inhibitor and application thereof | 加利福尼亚技术学院 | 2025-05-16 | — | — | CN | disclosed |
| US-20230116602-A1 | MCL1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| WO-2022216946-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-4038072-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114746428-A | MCL1 inhibitor and application thereof | 加利福尼亚技术学院 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021067827-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172549-A1 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | disclosed |
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233918-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES | MAPT, PRMT1, PSEN1 | MAPT 1/4885MEN1 3362/4885KMT2A 701/4885 |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | MAPT 4321/4885MEN1 4692/4885KMT2A 2333/4885 |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | TGFBR1, SMAD3, ALK | MAPT 3476/4885MEN1 3463/4885KMT2A 2816/4885 |
| US-20130172549-A1 | Heteroaryl amide derivatives | HCAR2, PIGS, GPR52 | MAPT 4321/4885MEN1 4692/4885KMT2A 2333/4885 |
| US-20230116602-A1 | MCL1 INHIBITORS AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | MAPT 3555/4885MEN1 399/4885KMT2A 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.